Cerebral Amyloid Angiopathy
Neurology·MeSH: Cerebral Amyloid Angiopathy
Prevalence
0.1 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| ALN-APP | ALNYLAM PHARMACEUTICALS, INC. (ALNY) |
Frequently asked questions
How many drugs are in development for Cerebral Amyloid Angiopathy?
BioSniper tracks 1 drug in development for Cerebral Amyloid Angiopathy across 1 company.
How many clinical trials target Cerebral Amyloid Angiopathy?
There are 1 clinical trial targeting Cerebral Amyloid Angiopathy tracked by BioSniper.
What is the prevalence of Cerebral Amyloid Angiopathy?
The estimated prevalence of Cerebral Amyloid Angiopathy is approximately 0.1 per 100,000 population.
Deep-dive into Cerebral Amyloid Angiopathy
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis